Spencer S. Eccles Health Sciences Library, University of Utah
Abstract
Dasatinib (Sprysel) is a new second generation oral Bcr-Abl tyrosine kinase inhibitor, approved for first line treatment of patients with chronic myelogenous leukemia (CML). According to phase 1 and 2 studies published to date ophthalmological secondary effects of dasatinib, are practically non-existent or trivial. Resent literature case report suggest the possibility of secondary optic neuropathy caused by the drug
